A review of relevant law reveals that the Trump administration is not nearly as hampered by antitrust law as the pharmaceutical benefits manager industry argues. Antitrust law does not prohibit manufacturers from offering discounts on drug prices, and antitrust law cannot justify the industry’s current aggressive use of rebates, according to a piece co-authored by Kevin Schulman.

https://www.healthaffairs.org/do/10.1377/hblog20190402.468158/full/

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2024 Business School Alliance for Health Management

or

Log in with your credentials

or    

Forgot your details?

or

Create Account